Osler Diagnostics: The company raised $85 million of Series C venture funding from Braavos Investment Advisers, M&G, and Oxford Science Enterprises on November 7, 2022. Lansdowne Partners also participated in the round. The company is a developer of a blood sampling and testing device designed to test for biomarkers.
Faraday Pharmaceuticals: The company raised $52.8 million of venture funding from undisclosed investors on November 7, 2022. The company is a developer of novel therapeutics designed to offer elemental reducing agents.
Juvena Therapeutics: The company raised $41 million of Series A venture funding in a deal led by Mubadala Capital-Ventures and Horizons Ventures on an undisclosed date. Compound, Felicis Ventures, Intersect VC, BoxOne Ventures, Manta Ray Ventures, Transform VC, Alumni Ventures, Plum Alley Investments, Karl Pfleger, Jeff Dean, Bison Ventures and IRONGREY also participated in the round. The company is a developer of a biopharmaceutical drug discovery platform intended to discover novel protein-based therapeutics.
Nabsys: The company raised $38 million of Series B venture funding from Hitachi High-Technologies on November 9, 2022. The company is a developer of genome-mapping products designed to analyze whole genome mapping in high definition.
Ncardia: The company raised EUR 30 million of venture funding from undisclosed investors on November 7, 2022, putting the company’s pre-money valuation at EUR 80.00 million. The company is an operator of a biotechnology business created to provide technologies to expedite drug discovery and development processes.
Lipidio Pharmaceuticals: The company raised $20 million of Series A venture funding from FPWR, 3E Bioventures Capital, and Alethea Capital Management on November 10, 2022. Nancy Chang, John Maraganore, Brent Saunders, and other undisclosed investors also participated in the round. The company is a developer of therapeutic drugs designed to treat diseases associated with excess body fat.
NRG Therapeutics: The company raised GBP 16 million of Series A venture funding in a deal led by Omega Funds on November 9, 2022. Parkinsons UK and Brandon Capital also participated in the round. The company is an operator of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function.
CuraSen: The company raised $15 million of venture funding from undisclosed investors on November 9, 2022. The company is an operator of a biopharmaceutical business intended for the development of novel treatments for neurodegenerative diseases.
CranioVation: The company raised $14 million of venture funding from undisclosed investors on November 9, 2022. The company is a developer of a surgical device designed to treat aggressive brain tumors using light delivered via a minimally invasive device.
MapLight Therapeutics: The company raised $12 million of venture funding from undisclosed investors on November 10, 2022. The company is an operator of a biopharmaceutical business intended to discover novel treatments for brain disorders.
Metabolon: The company raised $10.0 million of venture funding from undisclosed investors on November 10, 2022. The company is a developer of analytical software designed to decipher discrete chemical signals from genetic and non-genetic factors to reveal biological pathways.
Wesper: The company raised $7.5 million in Series A venture funding from Ceros Financial Services and Krillion Ventures on November 8, 2022, putting the company’s pre-money valuation at $38 million. The company is a developer of a topical patch for sleep medicine.